Compare Dishman Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ASTRAZENECA PHARMA DISHMAN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 25.1 116.0 21.6% View Chart
P/BV x 3.3 35.5 9.4% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-18
DISHMAN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,278 29.3%   
Low Rs129883 14.6%   
Sales per share (Unadj.) Rs197.8228.4 86.6%  
Earnings per share (Unadj.) Rs21.210.4 204.6%  
Cash flow per share (Unadj.) Rs34.716.3 213.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.998.8 182.1%  
Shares outstanding (eoy) m80.6925.00 322.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.7 26.9%   
Avg P/E ratio x11.9104.2 11.4%  
P/CF ratio (eoy) x7.266.4 10.9%  
Price / Book Value ratio x1.410.9 12.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30627,008 75.2%   
No. of employees `0000.81.4 61.1%   
Total wages/salary Rs m5,3551,535 348.8%   
Avg. sales/employee Rs Th19,252.74,210.9 457.2%   
Avg. wages/employee Rs Th6,459.51,132.2 570.5%   
Avg. net profit/employee Rs Th2,064.1191.1 1,080.2%   
INCOME DATA
Net Sales Rs m15,9615,710 279.5%  
Other income Rs m265123 216.7%   
Total revenues Rs m16,2265,833 278.2%   
Gross profit Rs m4,103463 886.4%  
Depreciation Rs m1,091147 739.9%   
Interest Rs m9440-   
Profit before tax Rs m2,334438 532.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624179 348.6%   
Profit after tax Rs m1,711259 660.4%  
Gross profit margin %25.78.1 317.1%  
Effective tax rate %26.740.8 65.4%   
Net profit margin %10.74.5 236.3%  
BALANCE SHEET DATA
Current assets Rs m11,0183,209 343.3%   
Current liabilities Rs m9,5172,070 459.9%   
Net working cap to sales %9.420.0 47.1%  
Current ratio x1.21.6 74.7%  
Inventory Days Days11072 152.7%  
Debtors Days Days3535 99.8%  
Net fixed assets Rs m16,304790 2,063.0%   
Share capital Rs m16150 322.8%   
"Free" reserves Rs m12,9072,419 533.5%   
Net worth Rs m14,5162,469 587.8%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8054,605 647.2%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 43.2%   
Return on assets %8.95.6 158.4%  
Return on equity %11.810.5 112.3%  
Return on capital %17.517.7 98.8%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,952300 1,653.0%   
Fx outflow Rs m6972,015 34.6%   
Net fx Rs m4,255-1,715 -248.0%   
CASH FLOW
From Operations Rs m2,78688 3,170.0%  
From Investments Rs m-1,529-94 1,633.4%  
From Financial Activity Rs m-941NA-  
Net Cashflow Rs m316-6 -5,550.9%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 12.7 15.7 80.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 9.1 242.9%  
Shareholders   46,261 12,856 359.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  AUROBINDO PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - DR. REDDYS LAB COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS